1 Personalized Medicine World Conference- Silicon Valley
Visit Q2 Solutions Booth #17, meet our Experts and attend our podium presentation to discover how genomics enhances clinical Immuno-oncology trials
About This Event
Attend our Podium Presentation during Genetics Informed Personalized Immunotherapy Session (Track 2) and Discover how Genomics Enhances Clinical Immuno-oncology Trials
Abstract: Immuno-oncology is developing at an unprecedented rate, with information integrated into drug development almost simultaneously. Accelerated bench-to-bedside practice brings great opportunity, but challenges emerge in the application of genomics to clinical trials. We will discuss test services developed by Q2 Solutions to enable translation of Immuno-oncology genomics in clinical trials.
Location: Computer History Museum
Speaker: Patrice Hugo, Ph.D., Chief Scientific Officer, Q2 Solutions
Date and Time: Tuesday, January 26, 2016 at 3:00 pm
We look forward to meeting you in Silicon Valley.
Chief Scientific Officer
Patrice Hugo, Ph.D. is chief scientific officer of Q2 Solutions, a Quintiles Quest Joint Venture. Dr. Hugo leads the organization’s global scientific strategy and implementation, developing and accelerating strategies to help improve human health through innovation that transforms science and data into actionable medical insights.
Dr. Hugo brings more than 25 years of senior scientific leadership experience with extensive management expertise in laboratory operations applied to diagnostics, therapeutic targets and clinical trials. Most recently, Dr. Hugo was Associate Vice President and Chief Scientist at Laboratory Corporation of America (LabCorp). He has held several other senior leadership positions at companies including LabCorp, Clearstone Central Laboratories, Caprion and PROCREA BioSciences. A noted industry expert, Dr. Hugo has more than 75 scientific publications in internationally renowned journals. He also is active in a number of industry organizations, including his role on the Board of Directors for the non-for-profit Personalized Medicine Partnership for Cancer in Quebec, Warnex offering analytical and bioanalytical services and his role as a Steering Committee Member for the Biomarker Factory.
Dr. Hugo obtained his Ph.D. at McGill University and completed five years of post- doctoral fellowship at the Walter Elisa Hall Institute in Australia, and Howard Hughes Medical Institute in Denver, Colorado.